Live ticker
Activity
Every trade on Endcap, live. The tape updates in place as new positions clear.
Sign in to filter this view to traders you follow. For now you’re seeing the global tape.
50 trades
- @blakevargasBoughtYESat 63¢+78 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @skylerunderhillBoughtNOat 25¢+250 SPon Most-funded GLP-1 weight-loss app of 2026: Hims Weight Loss
- @reesekhanBoughtNOat 42¢+21 SPon Generic GLP-1 launch in US: Q1 2026
- @caseyokaforBoughtYESat 42¢+43 SPon Most-funded GLP-1 weight-loss app of 2026: Sequence (WW)
- @blakeunderhillBoughtNOat 34¢+49 SPon Most-funded GLP-1 weight-loss app of 2026: Found
- @alexkhanBoughtNOat 40¢+17 SPon Most-funded GLP-1 weight-loss app of 2026: Hims Weight Loss
- @rileykimBoughtYESat 69¢+18 SPon Generic GLP-1 launch in US: 2027 or later
- @jordanvargasBoughtNOat 43¢+56 SPon First GLP-1 brand to 1M active subscribers: Ro
- @micahbennettBoughtNOat 31¢+45 SPon First GLP-1 brand to 1M active subscribers: Calibrate
- @sashavargasBoughtYESat 62¢+37 SPon First GLP-1 brand to 1M active subscribers: Sequence
- @tatumchenBoughtYESat 40¢+54 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Eli Lilly (tirzepatide)
- @wrenvargasBoughtNOat 54¢+16 SPon First GLP-1 brand to 1M active subscribers: No brand discloses
- @haydenlopezBoughtYESat 53¢+30 SPon Generic GLP-1 launch in US: Q3 2026
- @averylopezBoughtNOat 34¢+36 SPon Tirzepatide compounding outcome: Status quo (compounding continues)
- @sashavargasBoughtYESat 83¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Sequence (Weight Watchers)
- @frankieblakeBoughtYESat 59¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Found
- @parkerokaforBoughtYESat 59¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Hims
- @skylercarrilloBoughtYESat 62¢+63 SPon First GLP-1 telehealth to raise a mega-round in 2026: Calibrate
- @juneyoonBoughtYESat 57¢+21 SPon Tirzepatide compounding outcome: Full ban with no shortage carve-out
- @darbyblakeBoughtYESat 52¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: PlushCare
- @blakeunderhillBoughtNOat 47¢+68 SPon Tirzepatide compounding outcome: Full ban with no shortage carve-out
- @rowanmonroeBoughtYESat 52¢+63 SPon First GLP-1 telehealth to raise a mega-round in 2026: Ro
- @harperyoonBoughtYESat 57¢+60 SPon Tirzepatide compounding outcome: Expanded permissions
- @tatumkimBoughtYESat 64¢+16 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Tied within 1pp
- @briarlopezBoughtYESat 55¢+24 SPon First GLP-1 telehealth to raise a mega-round in 2026: Hims
- @tatumwalshBoughtYESat 57¢+46 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @elliotalvarezBoughtYESat 49¢+27 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @juneyoonBoughtNOat 54¢+25 SPon Most-funded GLP-1 weight-loss app of 2026: Calibrate
- @haydenlopezBoughtNOat 53¢+65 SPon Tirzepatide compounding outcome: Restricted with shortage carve-out
- @kaidiazBoughtNOat 45¢+16 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Novo Nordisk (semaglutide)
- @logantorresBoughtYESat 71¢+60 SPon Generic GLP-1 launch in US: Q4 2026
- @kaiunderhillBoughtYESat 73¢+36 SPon Generic GLP-1 launch in US: Q2 2026
- @marloweriveraBoughtYESat 49¢+17 SPon Tirzepatide compounding outcome: Status quo (compounding continues)
- @skylerunderhillBoughtNOat 63¢+17 SPon Generic GLP-1 launch in US: Q3 2026
- @skylercarrilloBoughtYESat 45¢+69 SPon First GLP-1 brand to 1M active subscribers: Found
- @sagecarrilloBoughtNOat 44¢+38 SPon Generic GLP-1 launch in US: Q1 2026
- @skylerunderhillBoughtNOat 68¢+26 SPon Generic GLP-1 launch in US: 2027 or later
- @kaidiazBoughtNOat 34¢+62 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Eli Lilly (tirzepatide)
- @rowandiazBoughtNOat 46¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Ro
- @darbyblakeBoughtYESat 57¢+45 SPon First GLP-1 telehealth to raise a mega-round in 2026: Calibrate
- @skylerunderhillBoughtYESat 44¢+63 SPon First GLP-1 telehealth to raise a mega-round in 2026: PlushCare
- @sashahayesBoughtNOat 37¢+69 SPon Most-funded GLP-1 weight-loss app of 2026: Sequence (WW)
- @drewhayesBoughtYESat 52¢+43 SPon First GLP-1 telehealth to raise a mega-round in 2026: Found
- @briarlopezBoughtNOat 33¢+77 SPon First GLP-1 brand to 1M active subscribers: Calibrate
- @finleyyoonBoughtNOat 65¢+37 SPon Generic GLP-1 launch in US: Q3 2026
- @lanejensenBoughtNOat 57¢+71 SPon Most-funded GLP-1 weight-loss app of 2026: Calibrate
- @juneyoonBoughtNOat 48¢+80 SPon First GLP-1 brand to 1M active subscribers: Ro
- @rowandiazBoughtNOat 46¢+80 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Novo Nordisk (semaglutide)
- @parkersantosBoughtNOat 37¢+80 SPon First GLP-1 brand to 1M active subscribers: Found
- @reesekhanBoughtNOat 46¢+20 SPon Tirzepatide compounding outcome: Expanded permissions